The FDA Has Cleared Teleflex's QuikClot Control+ Hemostatic Device To Include Mild, Moderate Bleeding In Cardiac Surgical Procedures And Bone Surface Bleeding Following A Sternotomy
Portfolio Pulse from Benzinga Newsdesk
The FDA has expanded the clearance for Teleflex's QuikClot Control+ Hemostatic Device to include mild and moderate bleeding in cardiac surgical procedures and bone surface bleeding following a sternotomy.
August 01, 2023 | 10:59 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teleflex's QuikClot Control+ Hemostatic Device has received expanded FDA clearance, potentially increasing its market and usage.
The FDA's expanded clearance for Teleflex's QuikClot Control+ Hemostatic Device means it can now be used in more surgical procedures. This could potentially increase its market and usage, which could have a positive impact on Teleflex's revenues and stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100